Item 1A. RISK FACTORS

The following risk factor updates the previously disclosed risk factor regarding certain material weaknesses in our internal control over financial reporting, as included under Item 1A “Risk Factors” in our 2023 Form 10-K. There have been no other material changes to our risk factor disclosures since our 2023 Form 10-K. The risk factors described in the 2023 Form 10-K and in this report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, or operating results.

We have identified material weaknesses in our internal control over financial reporting, and if our remediation of such material weaknesses is not effective, it could impact our ability to produce timely and accurate financial statements or comply with applicable laws and regulations.

As more fully disclosed in the 2023 Form 10-K/A, Part II, Item 9A, “Controls and Procedures,” we have identified material weaknesses in our internal control over financial reporting for the fiscal year ended December 29, 2023. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

In the course of preparing our consolidated financial statements as of and for the fiscal year ended December 29, 2023, as included in the 2023 Form 10-K, we identified a material weakness related to the accounting for the Company’s business combination of Transporeon. This included lack of appropriate oversight of third-party valuation specialists and insufficient design and operating effectiveness of management review controls, including controls over the completeness and accuracy of certain assumptions used in the valuation of acquired intangible assets.

Subsequent to the filing of the 2023 Form 10-K, management re-evaluated the effectiveness of our internal control over financial reporting. Based on this re-evaluation, we identified additional material weaknesses related to certain ITGCs, undue reliance on controls over IT interfaces, and the evaluation of standalone selling prices utilized in the accounting for revenue, all of which support the Company’s financial reporting processes.

As previously disclosed, the Company had delayed the filing of this report and its Quarterly Reports on Form 10-Q for the periods ended March 29, 2024 (the “Q1 2024 10-Q”) and June 28, 2024 (the “Q2 2024 10-Q”) until the assessment of the impacts of the matters described above was complete. As a result of the delayed filings, the Company has not been in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the SEC.

Based on materials submitted to The Nasdaq Stock Market LLC (“Nasdaq”) in connection with the delayed Q1 2024 10-Q and Q2 2024 10-Q filings, the Company received an extension until November 11, 2024 to regain compliance with the Listing Rule. When the Company did not meet this deadline and had not filed this report by its due date, the Company received a notification from Nasdaq (the “Nasdaq Notice”), informing the Company that Nasdaq had initiated a process (the “Staff Determination”), which could result in the delisting of the Company’s common stock from Nasdaq if the Company did not regain compliance with the Listing Rule. The Nasdaq Notice and the Staff Determination had no immediate effect and did not immediately result in the suspension of trading or delisting of the Company’s securities.

The Company intends to regain compliance with the Listing Rule by filing this report and the Q1 2024 10-Q and the Q2 2024 10-Q and expects thereafter to receive a letter from Nasdaq informing the Company that it has regained compliance. As a result of our failure to timely meet our SEC reporting obligations, we will be unable to use Form S-3 for the twelve months after we made our delayed filings. This could make accessing the capital markets during this period more costly or less efficient.

Furthermore, our management, under the oversight of the Audit Committee, has been taking actions to implement our remediation plan as described more fully in Part II, Item 9A, “Controls and Procedures” in the 2023 Form 10-K/A. Unless otherwise described herein, the material weaknesses will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded through testing that these controls are operating effectively.

If we are not able to successfully remediate these material weaknesses, there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be presented or detected on a timely basis. Moreover, if we

Table of Contents

uncover additional material weaknesses, our financial statements may be inaccurate, and we may be unable to comply with our SEC filing obligations, which could prevent us from using Form S-3 or result in a Nasdaq delisting.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(a) None.

(b) None.

(c) None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.